In vitro activation of anti-CD3 and anti-CD28 antibodies allows IFN-γ to generate CD4 + CD25+ regulatory T cells (iTregs) from CD4 + CD25− T cells in GBS patients (24). This evidence concerns the gene CD28 and Guillain-Barre syndrome.